Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

NCT: NCT04972097 · COMPLETED

NCT IDNCT04972097
StatusCOMPLETED
Start Date2022-03-29
Completion2024-08-14
SponsorAngiodynamics, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

Pivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.

Frequently Asked Questions

What is Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue?

Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue is a clinical trial registered under NCT04972097. Current status: COMPLETED.

What is the status of NCT04972097?

The current status of NCT04972097 (Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue) is: COMPLETED.

When did Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue start?

Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue started on 2022-03-29.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.